Phase II Pharmacodynamic Trial to Determine the Effects of Bardoxolone Methyl on eGFR in Patients With Type 2 Diabetes and Chronic Kidney Disease
A phase 2 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 129 participants.
Also called NCT01053936
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; no masking; primary purpose treatment
- Phase
- Phase 2
- Enrolled
- 129 participants
- Sponsor
- Registry
-
NCT01053936
-
- Started
- (actual)
- Primary completion
- (actual)
- Completion
- (actual)
- Countries
- United States
- Registry status
- Completed
Technical summary
Registry record NCT01053936. Randomized; no masking; primary purpose treatment. Start 2010-01-31 (actual); primary completion 2010-12-31 (actual). Results not posted.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- Phase II Pharmacodynamic Trial to Determine the Effects of Bardoxolone Methyl on eGFR in Patients With Type 2 Diabetes and Chronic Kidney Disease
- Condition
- Renal Insufficiency, Chronic
- Condition
- Diabetes Mellitus, Type 2
- Intervention (Drug)
- Bardoxolone methyl (amorphous dispersion)
- Lead sponsor
- Biogen
Record details
- Record id
cardio:ct-nct01053936- Content hash
f432c246b7e00d293b85009c0cbba2dcdb03c72da6dc0d8b2d0ea1b1f36cacab